Xcout Intel
AM Pharma
AM-Pharma is a biopharmaceutical company based in Utrecht, the Netherlands, focused on developing proprietary recombinant human alkaline phosphatase therapeutics like ilofotase alfa for severe medical conditions.
Subscribe to see AM Pharma’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
AM Pharma at a glance
AM Pharma is a biotechnology company headquartered in Netherlands. It has raised at least $207.1M across the 3 funding rounds on record. Its most recent funding round, Debt Financing, raised $51.7M in March 2020. Xcout tracks 9 named people at AM Pharma, including Juliane Bernholz (Chief Executive Officer).
AM Pharma leadership
- Juliane BernholzChief Executive Officer
- Timothy HerpinChief Business Officer
- Liesbeth HofSenior Director PMO
- Matthias WinkelSenior Director Clinical Data Management
- Sjoert van der BergSenior Director Finance
- Maarten KraanSenior Medical Advisor
3 more named people on record for AM Pharma, with roles, board committees and tenure — see the full roster →
AM Pharma funding rounds
At least $207.1M raised across the 3 rounds on record. Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Debt Financing | $51.7M | 1 named | |
| — | $133M | 10 named | |
| Series C | $22.4M | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Investors
AM Pharma competitors
A few of AM Pharma's closest competitors — see the full list of competitors and alternatives →
Ultragenyx Pharmaceutical Inc. is an American biopharmaceutical company involved in the research and development of novel products for treatment of rare and ultra-rare genetic diseases for which there are typically no approved treatments and high unmet medical need. The company works with multiple drug modalities including biologics, small molecule, gene therapies, and ASO and mRNAs in the disease categories of bone, endocrine, metabolic, muscle and CNS diseases.
Amolyt Pharma is a biotechnology company focused on developing peptide therapeutics for rare endocrine and metabolic diseases. Its lead program, eneboparatide, is being developed for chronic hypoparathyroidism, serving patients with serious hormone-related disorders and the clinicians who treat them.
Amicus Therapeutics, Inc. is an American biopharmaceutical company focused on discovering and delivering advanced therapies for rare diseases. The company is publicly traded on Nasdaq and maintains its global corporate headquarters in Princeton, New Jersey.
Alesta Therapeutics is a clinical-stage biotechnology company based in Leiden, Netherlands, dedicated to developing novel oral small-molecule therapies targeting GCN2 for underserved rare diseases.
Applied Therapeutics, Inc. is a biopharmaceutical company headquartered in New York City, focused on developing novel product candidates targeted at disease targets involving enzyme and metabolic pathways.
Amplio Pharma is a pharmaceutical company founded in 2020 that develops proprietary drug products to significantly amplify the efficacy of existing pharmaceutical treatments. The company is headquartered in Leiden, Netherlands.
Get AM Pharma's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on AM Pharma in Xcout Intel
- 9 named people with titles, LinkedIn and board committees
- 3 funding rounds with the investors in each, and who they co-invest with
- The full competitor set, tracking, exports and API access